Provides Additional Borrowing Capacity of Up to 10 million Euros Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Mauna Kea Technologies Announces Amendment to Existing Debt Agreement with IPF Partners
read more
Search Results
CONTACT 2 pivotal trial in pancreatic cysts has met primary and secondary endpoints demonstrating Cellvizio’s higher diagnostic performance compared to the current standard of care
Results from large, prospective, multi-center CONTACT 2 study published in Endoscopy, the official Journal of the European Society of...
Mauna Kea Technologies Reports Third Quarter 2018 Sales
Read the complete press release
Executive Leadership Transition to Support New Phase of Growth
Healthcare industry executive Robert L. Gershon to join as Chief Executive Officer and Board Member, bringing 30 years of commercial leadership...
Mauna Kea Technologies Announces First Published Report of Live “Tele-Cellvizio®” Utilization In Vivo between Surgeons and Remote Pathologists
Results of breakthrough PERSEE trial involving live transmission and robotized use of Cellvizio confocal miniprobe published online in Surgical...
Results from Large U.S. Prospective Multi-Center Clinical Trial on Detection of Barrett’s Esophagus with Cellvizio®
Results of the 8 non academic center trial publish online in Surgical Endoscopy, the official journal of SAGES, the Society of American...
Join the Mauna Kea Technologies 2018 Half Year Results
Sacha Loiseau, Founder, CEO and Christophe Lamboeuf, CFO will host an English-language conference call at 7:15 PM CEDT, Paris time (1:15 PM EDT, New...
nCLE Solution for Applications in Lung Cancer and Other Pulmonary Diseases during ERS 2018
The availability of the needle-based Cellvizio platform, now bearing CE mark, could be a game changer for the management of patients with certain...
Mauna Kea Technologies Reports Second Quarter and First Half 2018 Sales
Download the full press release here
Positive Results from Mayo Clinic Sponsored Prospective Multi-center Trial in Lung Transplant Patients
Cellvizio’s optical biopsy could become a safe and effective alternative to invasive biopsies in transplanted patients Mauna Kea...
20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating IBDs and Pancreatic Cysts at DDW 2018
Twenty accepted abstracts demonstrate growing clinical adoption and recognition of Cellvizio as a necessary tool for real-time optical biopsy in...
Mauna Kea Technologies obtains first ever FDA clearance for applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery
Pivotal regulatory milestone in high stakes applications Cellvizio first-to-market in key neurosurgery field Provides unique response to unmet needs...